Arca
Skip to content
Tools
Tools

GAG: Structural capsid protein

Protein in Human immunodeficiency virus 1 that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on GAG, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Lenacapavir

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        LenacapavirApprovedGilead SciencesSmall moleculeInhibitorStructural capsid protein inhibitor37

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Study of Twice Yearly Lenacapavir, Teropavimab, and Zinlirvimab in the Pediatric Population With HIV-1LenacapavirPhase 2 / Phase 3Not yet recruitingGilead SciencesNov 19, 2026
        People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for EffectivenessLenacapavirPhase 1Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)Nov 16, 2026
        Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIVLenacapavirPhase 4Not yet recruitingGilead SciencesNov 2, 2026
        Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus LevelsLenacapavirPhase 2RecruitingGilead SciencesSep 25, 2026
        Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentLenacapavirPhase 2 / Phase 3RecruitingGilead SciencesJul 16, 2026
        Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyLenacapavirPhase 3RecruitingGilead SciencesJul 6, 2026
        Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment RegimensLenacapavirPhase 3RecruitingGilead SciencesJul 6, 2026
        A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1LenacapavirPhase 2RecruitingGilead SciencesJun 12, 2026

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2366504, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.